vs

Side-by-side financial comparison of DORCHESTER MINERALS, L.P. (DMLP) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

DORCHESTER MINERALS, L.P. is the larger business by last-quarter revenue ($41.9M vs $27.6M, roughly 1.5× Zymeworks Inc.). DORCHESTER MINERALS, L.P. runs the higher net margin — 38.7% vs -71.0%, a 109.7% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 5.4%).

Dorchester Minerals, L.P. is a publicly traded master limited partnership based in the United States. It acquires, owns, and manages a diversified portfolio of royalty interests, net profit interests, and mineral properties associated with oil, natural gas, and natural gas liquids production across key onshore U.S. energy basins, delivering stable cash flow returns to its unitholders.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

DMLP vs ZYME — Head-to-Head

Bigger by revenue
DMLP
DMLP
1.5× larger
DMLP
$41.9M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+67.2% gap
ZYME
72.6%
5.4%
DMLP
Higher net margin
DMLP
DMLP
109.7% more per $
DMLP
38.7%
-71.0%
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
DMLP
DMLP
ZYME
ZYME
Revenue
$41.9M
$27.6M
Net Profit
$16.2M
$-19.6M
Gross Margin
Operating Margin
-80.1%
Net Margin
38.7%
-71.0%
Revenue YoY
5.4%
72.6%
Net Profit YoY
13.7%
34.3%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DMLP
DMLP
ZYME
ZYME
Q4 25
$41.9M
Q3 25
$35.4M
$27.6M
Q2 25
$32.4M
$48.7M
Q1 25
$43.2M
$27.1M
Q4 24
$39.7M
$31.0M
Q3 24
$53.5M
$16.0M
Q2 24
$37.4M
$19.2M
Q1 24
$31.0M
$10.0M
Net Profit
DMLP
DMLP
ZYME
ZYME
Q4 25
$16.2M
Q3 25
$11.2M
$-19.6M
Q2 25
$12.3M
$2.3M
Q1 25
$17.6M
$-22.6M
Q4 24
$14.2M
$-23.5M
Q3 24
$36.4M
$-29.9M
Q2 24
$23.6M
$-37.7M
Q1 24
$18.2M
$-31.7M
Operating Margin
DMLP
DMLP
ZYME
ZYME
Q4 25
Q3 25
-80.1%
Q2 25
-1.4%
Q1 25
-94.5%
Q4 24
-71.6%
Q3 24
-213.8%
Q2 24
-222.9%
Q1 24
-376.9%
Net Margin
DMLP
DMLP
ZYME
ZYME
Q4 25
38.7%
Q3 25
31.5%
-71.0%
Q2 25
38.1%
4.8%
Q1 25
40.9%
-83.5%
Q4 24
35.9%
-75.8%
Q3 24
68.1%
-186.6%
Q2 24
63.2%
-195.8%
Q1 24
58.6%
-315.6%
EPS (diluted)
DMLP
DMLP
ZYME
ZYME
Q4 25
Q3 25
$-0.26
Q2 25
$0.03
Q1 25
$-0.30
Q4 24
$-0.32
Q3 24
$-0.39
Q2 24
$-0.49
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DMLP
DMLP
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$41.9M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$320.1M
Total Assets
$309.6M
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DMLP
DMLP
ZYME
ZYME
Q4 25
$41.9M
Q3 25
$41.6M
$64.8M
Q2 25
$36.5M
$98.3M
Q1 25
$41.5M
$76.2M
Q4 24
$42.5M
$66.1M
Q3 24
$56.5M
$122.4M
Q2 24
$35.2M
$71.0M
Q1 24
$37.7M
$114.8M
Stockholders' Equity
DMLP
DMLP
ZYME
ZYME
Q4 25
Q3 25
$320.1M
Q2 25
$334.5M
Q1 25
$325.0M
Q4 24
$338.8M
Q3 24
$367.0M
Q2 24
$406.2M
Q1 24
$438.0M
Total Assets
DMLP
DMLP
ZYME
ZYME
Q4 25
$309.6M
Q3 25
$330.4M
$397.3M
Q2 25
$325.6M
$408.4M
Q1 25
$349.0M
$425.5M
Q4 24
$366.8M
$463.1M
Q3 24
$403.4M
$487.2M
Q2 24
$176.0M
$515.6M
Q1 24
$184.8M
$553.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DMLP
DMLP
ZYME
ZYME
Operating Cash FlowLast quarter
$34.3M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
2.12×
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DMLP
DMLP
ZYME
ZYME
Q4 25
$34.3M
Q3 25
$34.3M
$-31.4M
Q2 25
$30.5M
$12.1M
Q1 25
$33.4M
$-3.4M
Q4 24
$31.5M
$-41.5M
Q3 24
$43.7M
$-5.9M
Q2 24
$29.4M
$-25.0M
Q1 24
$28.0M
$-37.7M
Free Cash Flow
DMLP
DMLP
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-3.4M
Q4 24
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-37.9M
FCF Margin
DMLP
DMLP
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-12.6%
Q4 24
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-377.5%
Capex Intensity
DMLP
DMLP
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
1.8%
Cash Conversion
DMLP
DMLP
ZYME
ZYME
Q4 25
2.12×
Q3 25
3.07×
Q2 25
2.47×
5.21×
Q1 25
1.89×
Q4 24
2.21×
Q3 24
1.20×
Q2 24
1.25×
Q1 24
1.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DMLP
DMLP

Royalties$34.0M81%
Other$7.8M19%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons